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PERSPECTIVES ON DRUGS 
Preventing overdose  
deaths in Europe
The heroin epidemics that spread across Europe in the 1980s 
resulted in increasing numbers of overdose deaths among 
opioid users, which peaked for the first time around the turn of 
the millennium (1), and then again in 2008 with 8 174 cases. A 
new record number was registered in 2015 with 8 440 (EU28 
plus Turkey and Norway) overdose deaths. At country level, 
the most recent data from a number of EMCDDA reporting 
countries with relatively robust reporting systems, including 
Sweden, Lithuania, Ireland and the United Kingdom, show an 
increase.
Drug overdose continues to be a major cause of death, 
especially among young people in Europe, with recent data 
showing that young males are disproportionally affected, 
with 53.5 death cases per million among those aged 
35–39, compared to 14.3 deaths per million in the whole 
population. European countries have implemented a variety of 
approaches in their attempt to reduce overdose deaths at the 
national level using evidence-based interventions drawing on 
an understanding of individual and environmental risk factors.
I  Which factors increase the risk of fatal and non-fatal overdose?
The type of substance used, the route of administration 
and the health of the user all have an impact on the risk of 
overdose. Most overdose deaths are linked to the use of 
opioids, primarily the injection of heroin. Heightened levels of 
risk are also associated with the misuse of certain prescription 
More than 8 000 lives were reported to be 
lost to drug overdoses in Europe (EU28 
plus Turkey and Norway) in the past year 
and this is an underestimate. Reducing 
drug-related deaths therefore remains a 
major challenge for public health policy. 
This analysis describes some of the 
factors that increase the risk of fatal and 
non-fatal overdoses and a number of 
interventions developed to prevent these 
events.
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(1 ) In this analysis, the term ‘overdose deaths’ refers to deaths that are caused 
directly by the consumption of one or more illicit drug (http://www.emcdda.europa.
eu/activities/drd). Generally, overdose deaths occur shortly after the consumption 
of the substance(s). These deaths are also known as ‘poisonings’ or ‘drug-induced 
deaths’. 
.
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drugs (e.g. benzodiazepines), and the non-medical use of 
prescribed substitution medications and opioid analgesics 
(Giraudon et al., 2013). Potent synthetic opioids, such as 
fentanyl and its newer derivatives seem to play an increasing 
role in drug overdose in Europe. In addition, a substantial 
number of deaths involve polydrug use, particularly heroin in 
combination with other central nervous system depressants, 
such as alcohol or benzodiazepines.
A number of environmental factors increase the risk of 
drug overdose death including, in the case of opioid users, 
disruption of treatment provision or discontinuity of treatment 
and care. In certain situations, for example following 
detoxification or discharge from drug-free treatment, the 
tolerance of drug users to opioids is greatly reduced and as 
a result they are at particularly high risk of overdosing if they 
resume use. For these same reasons, inadequate throughcare 
between prison and community has also been identified as 
an important environmental risk factor (Zlodre and Fazel, 
2012). In a cohort study in England, differences in the risk 
of fatal opioid poisoning were identified, dependent on the 
type of treatment received: opioid users who received only 
psychological support appeared to be at greater risk than 
those who received opioid agonist pharmacotherapy (Pierce 
et al., 2016).
Finally, the lack of response or inadequate interventions by 
those witnessing overdoses, whether due to poor first aid 
knowledge, lack of access to effective medication or fear 
of legal repercussions, increases the risk of an overdose 
event having a fatal outcome (Frisher et al., 2012). A study in 
Bergen, Norway analysed differences in the time emergency 
services needed to arrive after overdose call-outs to private or 
public addresses. Ambulance response times were more likely 
to be longer for private locations; victims at private homes 
were more likely to be left at the scene after being treated and 
less likely to be transported to hospitals (Madah-Amiri et al., 
2016).
I  A range of responses: reducing the number of overdoses and preventing deaths
Drawing on the insights gained from risk and protective 
factors, the prevention of overdose deaths is generally 
addressed at two levels: the first involves a set of interventions 
geared towards the complete prevention of overdoses, 
while the second focuses on reducing fatal outcomes when 
overdoses do occur (Frisher et al., 2012). At both levels, 
strategies used include the scaling-up of known protective 
factors and the reduction of existing risks. Below, we introduce 
some of the most important strategies used by countries to 
address these intervention levels.
Increasing awareness of and information about overdose risks
As many drug users either are unaware of or seriously 
underestimate overdose risks, effective communication 
with users can act as a catalyst for reducing harm. Ideally, 
overdose prevention, education and counselling interventions 
would be provided by trained professionals as a matter of 
routine in the relevant health and primary care settings. 
Screening for overdose risk by those treating heroin users 
may contribute to reductions in overall mortality (Darke 
et al., 2011), while the use of overdose risk assessment 
interventions can assist the early identification of high-risk 
individuals. Twenty-eight EMCDDA reporting countries now 
report the distribution of overdose risk information, which is 
sometimes also available in different languages in order to 
be accessible to migrant drug users. There is increasing use 
of the internet and new channels of communication in this 
field, for example an e-health overdose risk assessment tool 
and overdose awareness videos, which may be projected in 
the waiting rooms of drugs facilities (e.g. http://vimeo.com/
album/1655129). Acknowledging the similarity of trends in 
mortality related to prescription opioids in Europe to those 
witnessed in the United States, countries now have an 
opportunity to adapt and scale up their prevention measures, 
reinforce surveillance and introduce improved regulatory 
measures to prevent deaths reaching epidemic proportions 
(Giraudon et al., 2013).
Provision of effective drug treatment and retention in 
treatment
There is convincing evidence that opioid substitution 
treatment (OST) substantially reduces the risk of mortality, 
as long as doses are sufficient and continuity of treatment 
is maintained (e.g. Degenhardt et al., 2011, Pierce, 2016). 
A prospective observational cohort study conducted in 
I  Facts and figures 
1.3 million high-risk opioid users in Europe, including 
Norway
8 440 overdose deaths in 2015 (EU28 plus Turkey and 
Norway) — Highest number of overdose deaths ever 
reported
54 deaths per million male population aged 35–39 due to 
overdose
667 000 cclients in opioid substitution treatment in 2015
10 countries with take-home naloxone programmes
8 European countries, including Switzerland, with drug 
consumption rooms
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Edinburgh confirmed that survival is increased by cumulative 
exposure to treatment (Kimber et al., 2010). As retention in 
drug treatment is a protective factor against overdose deaths, 
many European countries have given priority to increasing 
access to and coverage of treatment services.
With OST provision high, medical staff and service planners 
face the challenge of minimising the diversion of substitution 
medications to those without prescriptions while continuing to 
ensure that access to treatment is not impeded, for example 
by supervising consumption. Another widely used approach 
to reducing the risk of overdose is the implementation of 
good treatment practice, which involves the use of clinical 
guidelines and training doctors in prescribing practices 
(including benzodiazepine prescribing).
Improving throughcare between prison and community
Several interventions are recommended to help reduce the 
high number of overdose deaths among former prisoners in 
the period shortly after leaving prison (Merrall et al., 2010; 
Binswanger et al., 2013). These include pre-release education 
on overdose risks and prevention, continuation and initiation 
of substitution treatment (Degenhardt et al., 2014) and 
improved referral to aftercare and community treatment 
services (WHO Regional Office for Europe, 2010). In England, 
an individually randomised trial (NALoxone InVEstigation: 
N-ALIVE) aimed to test the hypothesis that giving naloxone on 
release to prisoners with a history of heroin injecting would 
reduce heroin overdose deaths in this population during 
the first 12 weeks after release, when there is an increased 
risk of drug-related death (Strang et al., 2013) (see further 
information in section ‘Improved bystander response’ and 
section 4: ‘Take-home naloxone’ below). Results from the 
third year of the Scottish National Naloxone Programme 
were released around the time of an interim analysis of the 
N-ALIVE trial in 2014. The results indicated a significantly 
lower proportion of opioid-related deaths had occurred 
within four weeks of prison release and it was decided to 
stop the N-ALIVE trial and to recommend naloxone be offered 
to all remaining prisoners upon release (Bird et al., 2016; 
Information Services Division, 2016; Parmar et al., 2016). 
I  Prevention of deaths in overdose situations
A second set of responses focuses on the prevention of 
fatalities when overdoses occur. These include a range of 
targeted interventions, the purpose of which is to enhance 
safety and ensure a rapid and effective response in 
emergency situations.
 Supervised drug consumption rooms
A total of 78 facilities for supervised drug consumption 
operate across six EU Member States (Denmark, France, 
Germany, the Netherlands, Luxembourg, Spain) and Norway, 
serving specific subgroups of highly marginalised and 
homeless drug users. Supervised drug consumption facilities 
aim to reach marginalised high-risk drug users and connect 
them to the wider network of care, to reduce the acute risks 
of diseases and overdose death associated with injecting or 
inhalative drug use, and to reduce public drug use (EMCDDA, 
2015a). Consumption rooms are highly targeted services, 
usually integrated within facilities that offer a broad range 
of other health and social services. They provide a safer 
drug use environment, advice on safer injecting and medical 
supervision, and are equipped to manage drug overdoses 
and reduce related morbidity and mortality. Millions of 
injections have been supervised and no overdose fatalities 
have occurred in the facilities. Evidence from robust studies 
documents increased access to health and social services 
among clients of supervised drug consumption facilities, 
and decreased public drug use and associated nuisance. A 
reduction in overdose mortality at the population level was 
documented in the city of Vancouver, in the local area where 
a supervised injecting facility operates (Marshall et al., 2011). 
See also Drug consumption rooms (EMCDDA, 2015b).
 Improved bystander response
Most overdoses occur when others are present and most 
injecting drug users have witnessed or experienced 
overdoses. Therefore, drug users themselves, or their friends 
and family, are likely to be both bystanders and potential 
first responders in emergency overdose situations (Strang et 
al., 2008). These human networks, with appropriate training 
and awareness raising, can be utilised to prevent overdose 
deaths. Interventions that aim to improve bystander responses 
consist of training peers and family members of drug users in 
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overdose prevention, recognition and response. A contextual 
analysis of ambulance call-outs to emergencies at private 
addresses (Madah-Amiri et al., 2016, see section on risk 
factors above) also indicates potential opportunities for peer 
overdose prevention interventions. In their new guidelines 
on community management of opioid overdose, the Word 
Health Organization (WHO) recommends that people 
likely to witness an opioid overdose should have access to 
naloxone — an effective antidote that can reverse opioid 
intoxication — and should be instructed in its administration 
(WHO, 2014). Evidence shows that educational and training 
interventions for peers and family members, complemented 
by take-home naloxone, help decrease overdose-related 
mortality. With evidence on its effectiveness growing, 
take-home naloxone provision has gained more attention 
in recent years. In January 2016, the EMCDDA launched 
a publication that brings together evidence as well as 
experiences from take-home naloxone projects in Europe 
and elsewhere (EMCDDA, 2016). 
I  Conclusions
Drug overdose deaths are preventable, and there is good 
evidence to show that specific interventions can both 
reduce the occurrence of overdose events and prevent 
fatal outcomes in overdose situations. The accumulated 
knowledge about risk and protective factors associated 
with overdoses, and about the successful management 
of overdose situations, has grown. Access to OST, which 
constitutes an important protective factor, has been 
substantially scaled up across the region. In addition, some 
countries have introduced new and targeted approaches, 
searching for innovative ways to identify those at risk of 
overdose, to raise risk awareness and to enable those who 
witness overdoses to intervene and prevent fatal outcomes.
Video: example of an overdose awareness video projected in waiting rooms of 
drugs facilities available on the EMCDDA website: emcdda.europa.eu/topics/pods/
preventing-overdose-deaths
I  Interactive element: videos
Video:Take-home naloxone programmes in Europe — overdose prevention 
available on the EMCDDA website: emcdda.europa.eu/topics/pods/preventing-
overdose-deaths
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Naloxone is an opioid antagonist medication used 
worldwide in emergency medicine to reverse respiratory 
depression caused by opioid overdose. Naloxone is listed 
by the World Health Organization as an essential medicine 
and is available in injectable form (intramuscular and 
intravenous) and in some countries as an intranasal spray, 
e.g. a nasal formulation has been approved by the U.S. 
Food and Drug Administration and is in use since 2015. The 
number of community-based opioid overdose prevention 
programmes that train potential bystanders, such as opioid 
users and their peers and family, on how to administer 
naloxone in order to reverse the effects of opioid overdose 
are increasing as overdose prevention response in the 
United States and Europe (CDC, 2012, Clark et al., 2014; 
Williams et al., 2014; Madah-Amiri et al., 2017). 
 
In its 2015 systematic review of 21 studies on take-home 
naloxone, the EMCDDA found evidence that educational 
and training interventions complemented by take-home 
naloxone decrease overdose-related mortality and that 
opioid-dependent patients and their peers involved in such 
programmes effectively improved their knowledge on the 
correct use of naloxone and the management of witnessed 
overdoses (EMCDDA, 2015). A meta-analysis of pooled data 
from four studies on bystander naloxone administration 
and from five studies on overdose education programmes 
(Giglio, Li and Di Maggio, 2015) confirmed these findings, 
finding an association of such programmes with increased 
odds of recovery and improved knowledge of overdose 
recognition and management in non-clinical settings. 
Currently, ten European countries (Denmark, Estonia, 
France, Germany, Italy, Ireland, Lithuania, Norway, Spain 
and the United Kingdom) report the existence of take-home 
naloxone programmes or local projects, some of which are 
small and time-limited. Scotland and Wales run nationwide 
programmes of naloxone distribution to high-risk users 
in the community and provide the medication to inmates 
released from prison. A comparison of the proportion of 
opioid-related deaths that occurred within four weeks of 
release from prison before (2006–10) and after (2011–13) 
the introduction of a national naloxone programme in 
Scotland showed a significant reduction from 9.8 % to 6.3 % 
of all opioid related deaths (Bird et al., 2016). 
 
As increased access to the opioid antagonist naloxone can 
reduce opioid-related morbidity and mortality, many US 
states have changed policies and legislation to increase 
layperson access to naloxone. For example, 44 states permit 
naloxone to be prescribed for administration to a person 
with whom the prescriber does not have a prescriber-patient 
relationship. Furthermore, pharmacy naloxone dispensing is 
encouraged (Davis and Carr, 2016). 
 
In European countries as well, legislative reform may be 
needed to allow the low-threshold provision of naloxone, 
a measure regarded as a low-cost approach that can 
empower healthcare workers and people who use drugs to 
save lives (WHO, 2014, p. 9).
Peer naloxone distribution  
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